Alexander Shulgin included 5-MeO-DPT in a subsection in the5-MeO-DET entry of his bookTiHKAL (Tryptamines I Have Known and Loved).[1] He did not explicitly provide a dose range orduration for 5-MeO-DPT, but did report having tried it at doses of 4 to 8.4mgorally, with 4mg producing only threshold effects and doses of 6 to 8.4mg being more meaningfully active.[1] In a subsequent literature review however, Shulgin gave an explicitly defined dose range of 6 to 10mg orally.[7] Itsonset was described as being 12minutes to within 1hour and its duration was 2 to 4hours.[1]
According to Shulgin, 5-MeO-DPT's actions are ambiguous and not totally positive.[1] This led to him tucking discussion of the drug away in the 5-MeO-DET entry ofTiHKAL as opposed to giving 5-MeO-DPT its own entry in the book.[1] The effects of 5-MeO-DPT were only vaguely described.[1] The 4mg dose produced only threshold effects described as "something".[1] At the 6mg dose, the effects included possibleeroticism, not too muchlightheadedness, and comfortableness, with a plus-two rating on theShulgin Rating Scale.[1][8] On the other hand, at the 8.4mg dose, there were5-MeO-DMT-like "head noises" or "bells" described as "bad" and an underlying 5-MeO-DMT-like "turn on" described as "good".[1][8] However, per Shulgin, while these effects alternated, the unpleasant negative effects overall outweighed the positive and desired effects.[1][8] There were no apparentcardiovascular effects at this dose.[1] Shulgin stated that he had "better things to do with my time" and did not further explore 5-MeO-DPT or evaluate higher doses.[1]
5-MeO-DPT's lowerhomologue 5-MeO-DET was found to produce unique and strongside effects such aslightheadedness,dizziness, andvertigo at low doses which precluded it from beingtolerated or used athallucinogenic doses.[1] Shulginsynthesized and tested 5-MeO-DPT in the hopes that the vertigo-related side effects of 5-MeO-DET would be reduced or eliminated while the hallucinogenic and other desired effects such assexual enhancement would be preserved.[1] However, while 5-MeO-DET-like side effects were not described, Shulgin nonetheless deemed 5-MeO-DPT an unpromising compound.[1]
Notes: The smaller the value, the more avidly the drug interacts with the site.Footnotes:a = Stimulation ofIP1Tooltip inositol phosphate formation.Sources:[8][9][10][11]
The drug fully substitutes for the serotonin5-HT2 receptor agonist andserotonergic psychedelicDOM in rodentdrug discrimination tests and partially substitutes for the serotonin 5-HT1A receptor agonist8-OH-DPAT in these tests followed by behavioral disruption at higher doses.[9] 5-MeO-DPT also substitutes for5-MeO-DMT in rodent drug discrimination tests.[13]
^Glennon RA, Young R, Rosecrans JA, Kallman MJ (1980). "Hallucinogenic agents as discriminative stimuli: a correlation with serotonin receptor affinities".Psychopharmacology.68 (2):155–8.doi:10.1007/BF00432133.PMID6776558.S2CID1674481.
^Nakamoto A, Namera A, Nishida M, Yashiki M, Kuramoto T, Kimura K (June 2007). "Identification and quantitative determination of 5-methoxy-N, N-di-n-propyltryptamine in urine by isotope dilution gas chromatography-mass spectrometry".Forensic Toxicology.25 (1):1–7.doi:10.1007/s11419-006-0018-y.S2CID9906203.
^Nakazono Y, Tsujikawa K, Kuwayama K, Kanamori T, Iwata YT, Miyamoto K, Kasuya F, Inoue H (January 2014). "Simultaneous determination of tryptamine analogues in designer drugs using gas chromatography–mass spectrometry and liquid chromatography–tandem mass spectrometry".Forensic Toxicology.32 (1):154–61.doi:10.1007/s11419-013-0208-3.S2CID25134125.
^abcGlennon RA, Titeler M, Lyon RA, Slusher RM (April 1988). "N,N-di-n-propylserotonin: binding at serotonin binding sites and a comparison with 8-hydroxy-2-(di-n-propylamino)tetralin".J Med Chem.31 (4):867–870.doi:10.1021/jm00399a031.PMID2965244.
^Glennon RA, Young R, Rosecrans JA, Kallman MJ (1980). "Hallucinogenic agents as discriminative stimuli: a correlation with serotonin receptor affinities".Psychopharmacology (Berl).68 (2):155–158.doi:10.1007/BF00432133.PMID6776558.
^Glennon RA, Gessner PK (April 1979). "Serotonin receptor binding affinities of tryptamine analogues".J Med Chem.22 (4):428–432.doi:10.1021/jm00190a014.PMID430481.
^Glennon RA, Rosecrans JA (1982). "Indolealkylamine and phenalkylamine hallucinogens: a brief overview".Neurosci Biobehav Rev.6 (4):489–497.doi:10.1016/0149-7634(82)90030-6.PMID6757811.
